Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.

BACKGROUND In patients with multivessel coronary artery disease who are undergoing percutaneous coronary intervention (PCI), coronary angiography is the standard method for guiding the placement of the stent. It is unclear whether routine measurement of fractional flow reserve (FFR; the ratio of maximal blood flow in a stenotic artery to normal maximal flow), in addition to angiography, improves outcomes. METHODS In 20 medical centers in the United States and Europe, we randomly assigned 1005 patients with multivessel coronary artery disease to undergo PCI with implantation of drug-eluting stents guided by angiography alone or guided by FFR measurements in addition to angiography. Before randomization, lesions requiring PCI were identified on the basis of their angiographic appearance. Patients assigned to angiography-guided PCI underwent stenting of all indicated lesions, whereas those assigned to FFR-guided PCI underwent stenting of indicated lesions only if the FFR was 0.80 or less. The primary end point was the rate of death, nonfatal myocardial infarction, and repeat revascularization at 1 year. RESULTS The mean (+/-SD) number of indicated lesions per patient was 2.7+/-0.9 in the angiography group and 2.8+/-1.0 in the FFR group (P=0.34). The number of stents used per patient was 2.7+/-1.2 and 1.9+/-1.3, respectively (P<0.001). The 1-year event rate was 18.3% (91 patients) in the angiography group and 13.2% (67 patients) in the FFR group (P=0.02). Seventy-eight percent of the patients in the angiography group were free from angina at 1 year, as compared with 81% of patients in the FFR group (P=0.20). CONCLUSIONS Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year. (ClinicalTrials.gov number, NCT00267774.)

[1]  S. Ellis.  Refining the art and science of coronary stenting. , 2009, The New England journal of medicine.

[2]  B. Meyer.  Directing Coronary Intervention Using Fractional Flow Reserve , 2009 .

[3]  E. Hannan,et al.  Drug-Eluting Stents vs Coronary-Artery Bypass Grafting in Multivessel Coronary Disease , 2008 .

[4]  Guido Germano,et al.  Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy , 2008, Circulation.

[5]  R. Higgins,et al.  Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. , 2008, The New England journal of medicine.

[6]  W. Howard,et al.  Optimal Medical Therapy with or without PCI for Stable Coronary Disease , 2008 .

[7]  Joseph S Alpert,et al.  [Universal definition of the myocardial infarction]. , 2008, Kardiologia polska.

[8]  Fred S Apple,et al.  Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.

[9]  U. Siebert,et al.  Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) study. , 2007, American heart journal.

[10]  William Wijns,et al.  Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. , 2007, Journal of the American College of Cardiology.

[11]  J. Granada,et al.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.

[12]  A. Schoenenberger,et al.  Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. , 2007, JAMA.

[13]  P. Serruys,et al.  Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. , 2007, The American journal of cardiology.

[14]  P. Serruys,et al.  Two‐year clinical outcome after coronary stenting of small vessels using 2.25‐mm sirolimus‐ and paclitaxel‐eluting stents: Insight into the RESEARCH and T‐SEARCH registries , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[16]  I. Iakovou,et al.  Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. , 2006, The American journal of cardiology.

[17]  G. Stone,et al.  Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. , 2006, Journal of the American College of Cardiology.

[18]  Patrick W Serruys,et al.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.

[19]  P. Teirstein.  The dueling hazards of incomplete revascularization and incomplete data. , 2006, Circulation.

[20]  Samin K. Sharma,et al.  Impact of Completeness of Percutaneous Coronary Intervention Revascularization on Long-Term Outcomes in the Stent Era , 2006, Circulation.

[21]  P. Serruys,et al.  Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. , 2006, Journal of the American College of Cardiology.

[22]  Gd Rotterdam.  Sirolimus-eluting stents remain superior to bare-metal stents at two years: Medium-term results from the Rapamycin-Elut-ing Stent Evaluated at Rotterdam Cardiology Hospital(RESEARCH) registry , 2006 .

[23]  M. Pfisterer,et al.  BASKET-LATE INVESTIGATORS, LATE CLINICAL EVENTS AFTER CLOPIDOGREL DISCONTINUATION MAY LIMIT THE BENEFIT OF DRUGELUTING STENTS: AN OBSERVATIONAL STUDY OF DRUG-ELUTING VERSUS BARE-METAL STENTS , 2006 .

[24]  P. Buser,et al.  Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .

[25]  J. Wheat,et al.  Gated myocardial perfusion SPECT. , 2005, Journal of nuclear medicine technology.

[26]  F. Schiele,et al.  One-year outcome of patients submitted to routine fractional flow reserve assessment to determine the need for angioplasty. , 2005, European heart journal.

[27]  M. Leesar,et al.  Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. , 2005, The American journal of cardiology.

[28]  Kurt Ulm,et al.  Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. , 2005, JAMA.

[29]  William Wijns,et al.  Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. , 2005, Journal of the American College of Cardiology.

[30]  P. Serruys,et al.  The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[31]  N. Pijls.  Optimum guidance of complex PCI by coronary pressure measurement , 2004, Heart.

[32]  L. Shaw,et al.  Prognostic value of gated myocardial perfusion SPECT , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[33]  G. Beller,et al.  Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. , 2003, Journal of the American College of Cardiology.

[34]  Habib Samady,et al.  Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. , 2002, The American journal of cardiology.

[35]  W. Wijns,et al.  Fractional Flow Reserve in Patients With Prior Myocardial Infarction , 2001, Circulation.

[36]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[37]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[38]  B. Zaret,et al.  Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. , 2000, Circulation.

[39]  N. Geller,et al.  Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. , 1997, Circulation.

[40]  P. H. van der Voort,et al.  Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. , 1996, The New England journal of medicine.

[41]  P. H. van der Voort,et al.  Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. , 1995, Circulation.

[42]  E. Topol,et al.  Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. , 1995, Circulation.

[43]  B. De Bruyne,et al.  Experimental Basis of Determining Maximum Coronary, Myocardial, and Collateral Blood Flow by Pressure Measurements for Assessing Functional Stenosis Severity Before and After Percutaneous Transluminal Coronary Angioplasty , 1993, Circulation.

[44]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .